What the FDA labels say about taking them together
Enzalutamide and gemfibrozil
Enzalutamide's FDA label of July 28, 2026 names gemfibrozil in its drug interactions section, and gemfibrozil's label names enzalutamide too. The gemfibrozil label: “(C) CYP2C8 Substrates: Gemfibrozil is a strong inhibitor of CYP2C8 and may increase exposure of drugs mainly metabolized by CYP2C8.”
Check it at the source: the enzalutamide FDA label on DailyMed (effective July 28, 2026, Astellas Pharma US, Inc.); the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC).
What does the enzalutamide label say about gemfibrozil?
Enzalutamide label, drug interactionsDrugs on XTANDI Strong CYP2C8 Inhibitors The coadministration of XTANDI with gemfibrozil (a strong CYP2C8 inhibitor) increases plasma concentrations of enzalutamide plus N-desmethyl enzalutamide, which may increase the incidence and severity of adverse reactions of XTANDI.
Xtandi label (Astellas Pharma US, Inc., May 25, 2021), drug interactionsDrugs that Inhibit CYP2C8 Co-administration of a strong CYP2C8 inhibitor (gemfibrozil) increased the composite area under the plasma concentration-time curve (AUC) of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold.
Source: FDA drug label (Xtandi, NDA213674), Astellas Pharma US, Inc., effective May 25, 2021 (SPL set 381cd215-78c9-4208-8595-7ae7a279b236), via openFDA
Source: FDA drug label (Xtandi), Astellas Pharma US, Inc., effective July 28, 2026 (SPL set b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf), via openFDA; the full label on DailyMed
What does the gemfibrozil label say about enzalutamide?
Gemfibrozil label, drug interactions(C) CYP2C8 Substrates: Gemfibrozil is a strong inhibitor of CYP2C8 and may increase exposure of drugs mainly metabolized by CYP2C8 (e.g., dabrafenib, enzalutamide, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone).
Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Enzalutamide | Gemfibrozil | |
|---|---|---|
| Labeled for | Prostate cancer | High cholesterol, Heart attack and coronary artery disease |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.104 per tablet 600 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once